Related Experiment Videos
Inhibition of cell-induced vitreous contraction by synthetic peptide derived from the collagen receptor binding
1Department of Ophthalmology, National Taiwan University Hospital, Taipei, Republic of China.
Abstract:
Cell-mediated tractional retinal detachment (TRD) is the end result of various intraocular proliferative disorders. Interactions between cells and extracellular matrix via cellular surface receptors, integrins, play an important role. Anti-adhesion therapy has been suggested as a promising way to treat the integrin-dependent pathological events. We tested three synthetic peptides, Gly-Arg-Gly-Asp-Ser (GRGDS), derived from the fibronectin receptor binding domain; Try-Ile-Gly-Ser-Arg (YIGSR), from the laminin receptor binding domain, and Ala-Asp-Gly-Glu-Ala (ADGEA), from the collagen receptor binding domain, to evaluate their inhibitory effect on cell-mediated matrix attachment and vitreous contraction in vitro, and on cell-induced TRD in rabbit eyes in vivo. Indirect immunofluorescent stain demonstrated both bovine retinal pigment epithelial (RPE) cells and rabbit dermal fibroblasts expressed the alpha 2 beta 1, alpha 5 beta 1 and alpha 6 beta 1 integrins, the collagen, fibronectin, and laminin receptors, respectively. GRGDS exhibited a broad spectrum of inhibitory activity on RPE cell attachment to extracellular matrices. YIGSR specifically inhibited RPE cell attachment to laminin, whereas ADGEA inhibited RPE cell attachment to collagen type I and IV. ADGEA inhibited RPE cell-induced vitreous contraction in a dose-dependent manner, whereas GRGDS and YIGSR had no effect. ADGEA (1250 micrograms/mL) delayed the development of TRD but did not prevent it. ADGEA was nontoxic to cells and retina, as demonstrated by cytotoxicity tests and histological examination. The synthetic peptide, ADGEA, and its analogs may be potential candidates for the treatment of cell-mediated collagenous contraction in the ocular tissues.
Insights
Synthetic peptide ADGEA shows potential for treating ocular conditions like tractional retinal detachment by inhibiting cell-matrix interactions. It demonstrated dose-dependent inhibition of vitreous contraction and delayed TRD development without toxicity.
Area of Science:
- Ophthalmology
- Cell Biology
- Biochemistry
Background:
- Tractional retinal detachment (TRD) results from proliferative disorders involving cell-matrix interactions via integrins.
- Anti-adhesion therapy targeting integrins is a potential treatment strategy for pathological events.
Purpose of the Study:
- To evaluate the inhibitory effects of three synthetic peptides (GRGDS, YIGSR, ADGEA) on cell-mediated matrix attachment, vitreous contraction, and TRD.
- To assess the toxicity and therapeutic potential of ADGEA in ocular tissues.
Main Methods:
- Tested synthetic peptides GRGDS, YIGSR, and ADGEA for their effects on retinal pigment epithelial (RPE) cell attachment and vitreous contraction in vitro.
- Evaluated ADGEA's efficacy in preventing cell-induced TRD in rabbit eyes in vivo.
- Performed immunofluorescence, cytotoxicity tests, and histological examinations.
Main Results:
- RPE cells expressed integrins for collagen, fibronectin, and laminin.
- ADGEA inhibited RPE cell attachment to collagen types I and IV, and dose-dependently inhibited vitreous contraction.
- GRGDS broadly inhibited RPE cell attachment, YIGSR specifically inhibited laminin attachment, and neither affected vitreous contraction.
- ADGEA delayed TRD development in vivo but did not prevent it, showing no ocular toxicity.
Conclusions:
- The synthetic peptide ADGEA shows promise for treating cell-mediated collagenous contraction in ocular tissues.
- ADGEA's specific inhibition of collagen interactions and vitreous contraction suggests therapeutic potential for TRD and related conditions.
- Further development of ADGEA and its analogs could lead to novel anti-adhesion therapies for proliferative vitreoretinopathy.